• A case report of an Egyptian family with familial hypercholesterolemia and an exonic LINE-1 insertion in LDLR
• A Clinical Case of Probable Sitosterolemia
• A Japanese Case of Familial Hypercholesterolemia with a Protein-truncating Variant in LDLR and a PCSK9 Variant without Significant Atherosclerosis but Showing Remarkable Achilles Tendon Thickening
• A Japanese Woman with Polygenic Familial Hypercholesteremia Who Exhibited Trivial Atherosclerosis
• A machine-learning algorithm using claims data to identify patients with homozygous familial hypercholesterolemia
• A novel equation for the estimation of low-density lipoprotein cholesterol in the Saudi Arabian population: a derivation and validation study
• Advances in familial hypercholesterolemia
• Advancing familial hypercholesterolaemia (FH) screening in primary care: an updated systematic review of systematic screening methods for identificaton of FH
• Algorithm for detection and screening of familial hypercholesterolemia in Lithuanian population
• Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
• Alirocumab: Pediatric First Approval
• Analysis of the Correlation between FH and PCSK9 and APOB Gene Mutations in Han and Mongolian Populations of the Hulunbuir
• ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab
• Aortic valve and arterial calcification in patients with familial hypercholesterolemia
• Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen
• Association Between Patient Sex and Familial Hypercholesterolemia and Long-Term Cardiovascular Risk Factor Management 5 Years After Acute Coronary Syndrome
• Association of Clinical Characteristics With Familial Hypercholesterolaemia Variants in a Lipid Clinic Setting: A Case-Control Study
• Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events
• Biochemical and Anthropometric Outcomes in Paediatric Patients with Heterozygous Familial Hypercholesterolemia after COVID-19 Pandemic Lockdowns: An Exploratory Analysis
• Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries
• Carotid intima-medial thickness in patients with severe hypertriglyceridemia
• Carotid intimamedia thickness in patients with severe hypertriglyceridemia
• Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
• Cluster analysis and visualisation of electronic health records data to identify undiagnosed patients with rare genetic diseases
• Communication: High-Density Lipoprotein-Specific Phospholipid Efflux in Familial Hypercholesterolemia
• Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)
• CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing
• Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study
• Diagnosis of Familial Hypercholesterolemia in Children and Young Adults
• Dysbetalipoproteinemia
• Emerging therapies for refractory hypercholesterolemia: a narrative review
• Establishing non-fasting reference values for plasma lipids levels based on age, sex, and puberty stage in a French-Canadian pediatric population
• Etiology and emerging treatments for familial chylomicronemia syndrome
• Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia
• Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
• Evinacumab: Mechanism of action, clinical, and translational science
• Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
• Exchange Transfusion: A Good Option for the Acute Treatment of Familial Chylomicronemia Syndrome in the Neonatal Period
• Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene
• Familial hypercholesterolemia
• Familial Hypercholesterolemia and Multiple Xanthomatosis
• Familial Hypercholesterolemia and Our Family's Heart History: From Atherosclerosis and Angina to Awareness and Advocacy
• Familial hypercholesterolemia care by Dutch pediatricians-mind the gaps
• Familial hypercholesterolemia with special focus on Japan
• Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial
• From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated
• Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease
• Generation of two familial hypercholesterolemia patient-specific induced pluripotent stem cell lines harboring heterozygous mutations in the LDLR gene
• Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia
• Genetic testing for familial hypercholesterolemia
• High Prevalence of Familial Hypercholesterolemia Due to the Founder Effect of the LDLR c.2271del Variant in Communities of Oaxaca, Mexico
• Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia
• Human In Vitro Oxidized Low-Density Lipoprotein (oxLDL) Increases Urinary Albumin Excretion in Rats
• Hypercholesterolaemia treated with inclisiran
• Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor
• Impact of 12-SNP and 6-SNP Polygenic Scores on Predisposition to High LDL-Cholesterol Levels in Patients with Familial Hypercholesterolemia
• Implementation of a primary-tertiary shared care model to improve the detection of familial hypercholesterolaemia (FH): a mixed methods pre-post implementation study protocol
• Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?
• Influence of Polygenic Background on the Clinical Presentation of Familial Hypercholesterolemia
• International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
• iPSC-Derived Endothelial Cells Reveal LDLR Dysfunction and Dysregulated Gene Expression Profiles in Familial Hypercholesterolemia
• It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States
• Knowledge, attitude, and practice of physicians towards familial hypercholesterolaemia in north regions of Saudi Arabia
• LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes
• LDLR c.415G > A causes familial hypercholesterolemia by weakening LDLR binding to LDL
• LDLR c.89_92dup: a novel frameshift variation in familial hypercholesterolemia
• LDLR gene rearrangements in Czech FH patients likely arise from one mutational event
• Lipid Disorders and Pregnancy
• Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
• Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
• Membrane Transporter of Serotonin and Hypercholesterolemia in Children
• Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report
• Novel LDLR variants affecting low density lipoprotein metabolism identified in familial hypercholesterolemia
• Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
• Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg
• Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry
• Plasma legumain in familial hypercholesterolemia: associations with statin use and cardiovascular risk markers
• Potentials of artificial intelligence in familial hypercholesterolemia: Advances in screening, diagnosis, and risk stratification for early intervention and treatment
• Predicted deleterious variants in ABCA1, LPL, LPA and KIF6 are associated with statin response and adverse events in patients with familial hypercholesterolemia and disturb protein structure and stability
• Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study
• Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: a retrospective observational study
• Putative Pathogenic Variants of <em>ABCG5</em> and <em>ABCG8</em> of Sitosterolemia in Patients With Hyper-Low-Density Lipoprotein Cholesterolemia
• Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan
• Recapitulating familial hypercholesterolemia in a mouse model by knock-in patient-specific LDLR mutation
• Reproductive Carrier Screening: Identifying Families at Risk for Familial Hypercholesterolemia in the United States
• Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors
• Role of statins in the management of dyslipidaemia
• Sex differences in familial hypercholesterolaemia
• Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia?
• Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia? Reply to Sanchez-Hernandez and Wagner [letter]
• Social cognition correlates of self-management behaviors in patients with familial hypercholesterolemia (FH): A meta-analytic review
• Spatial lipidomics of coronary atherosclerotic plaque development in a familial hypercholesterolemia swine model
• The diagnostic value of genetic testing in familial hypercholesterolemia in patients with premature myocardial infarction
• The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
• The Health History of First-Degree Relatives' Dyslipidemia Can Affect Preferences and Intentions following the Return of Genomic Results for Monogenic Familial Hypercholesterolemia
• The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia
• The Role of Reverse Cascade Screening in Children with Familial Hypercholesterolemia: A Literature Review and Analysis
• Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
• Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
• Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)